Actively Recruiting

Age: 18Years +
All Genders
NCT06575881

Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies

Led by Vanderbilt University Medical Center · Updated on 2026-05-06

200

Participants Needed

1

Research Sites

311 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias. The investigators aim to study: 1. the prevalence and mechanism of inducible ventricular tachycardia 2. pace-mapping to define the site of origin of ventricular arrhythmias 3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy. Participants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.

CONDITIONS

Official Title

Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 and older
  • Diagnosed with atrial fibrillation, frequent premature ventricular contractions, or ventricular tachycardia before age 60
  • Scheduled for catheter-based atrial fibrillation ablation (new or repeat), premature ventricular contraction ablation, or ventricular tachycardia ablation
  • Able to provide written, informed consent
  • Have a pathogenic or likely pathogenic variant in TTN or another cardiomyopathy gene (cases) or identified as a genotype-negative control
Not Eligible

You will not qualify if you...

  • Diagnosed with a genetic cardiomyopathy or arrhythmia syndrome before the ablation procedure
  • Variant of uncertain significance in the 'possibly pathogenic' subgroup (control group only)
  • Previous premature ventricular contraction or ventricular tachycardia ablation
  • Left ventricular ejection fraction less than 20%
  • Have a prosthetic mitral or aortic valve
  • Contraindication to heparin
  • Prior myocardial infarction

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

Loading map...

Research Team

D

Dakota Graherr, RN

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here